Clinical Trials
49 trialsNCT01998984 2025-03-10
Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
LEO Pharma
Phase 2 Completed
NCT02361216 2025-03-10
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
LEO Pharma
Phase 3 Completed
NCT01449513 2025-03-07
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
LEO Pharma
Phase 1 Completed
NCT01926496 2025-03-07
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
LEO Pharma
Phase 4 Completed
NCT01387711 2025-02-24
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology
LEO Pharma
Phase 1 Completed
NCT01787383 2025-02-24
A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities
LEO Pharma
Phase 3 Completed
NCT01803477 2025-02-24
Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm
LEO Pharma
Phase 1/2 Completed
NCT02124239 2025-02-24
Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions
LEO Pharma
Phase 1 Completed
NCT02377999 2025-02-24
Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts
LEO Pharma
Phase 2 Completed
NCT02406014 2025-02-24
Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp
LEO Pharma
Phase 4 Completed
NCT03546166 2023-07-21
PICABAS
Centre Hospitalier Universitaire de Nice
Phase 2 Completed
NCT04202445 2023-06-09
MIKADO
LEO Pharma
Completed
NCT02866695 2022-03-09
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
University of California, San Francisco
Phase 4 Completed
NCT01735942 2021-12-06
Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions
Northwestern University
Phase EARLY_PHASE1 Withdrawn
NCT02385318 2021-11-02
To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis
Padagis LLC
Phase 3 Completed
NCT02459795 2021-11-02
To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis
Padagis LLC
Phase 3 Completed
NCT02654769 2020-05-12
A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis
Actavis Inc.
Phase 3 Completed
NCT03200912 2020-01-14
An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis
Actavis Inc.
Phase 3 Completed
NCT02090465 2019-12-17
Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks
LEO Pharma
Completed
NCT02362152 2019-12-13
RAPID-ACT
LEO Pharma
Completed
NCT02421471 2019-12-13
PMS to Evaluate the Safety and Efficacy of Picato® Gel
LEO Pharma
Completed
NCT02990221 2019-09-24
Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy
University of Campania Luigi Vanvitelli
Phase 4 Completed
NCT02354391 2019-03-26
Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis
Pacific Dermaesthetics
Phase 2 Unknown
NCT02594436 2019-01-22
PrAKtice
LEO Pharma
Completed
NCT03508856 2018-04-26
Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin
Skin Laser & Surgery Specialists
Phase NA Completed
NCT02281682 2017-10-30
Akti
Maastricht University Medical Center
Phase 4 Unknown
NCT02748902 2017-07-17
Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.
TCR Medical Corporation
Phase 1 Completed
NCT02251652 2017-04-26
Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses
Icahn School of Medicine at Mount Sinai
Phase 4 Completed
NCT00375739 2016-01-28
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
Peplin
Phase 2 Completed
NCT00546611 2016-01-28
The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)
Peplin
Phase 1 Withdrawn
NCT00427050 2015-09-14
A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel
Peplin
Phase 2 Completed
NCT00850681 2015-09-09
A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
Peplin
Phase 1 Completed
NCT00850811 2015-09-09
A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
Peplin
Phase 1 Completed
NCT00917306 2015-04-15
A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)
Peplin
Phase 3 Completed
NCT00544297 2015-04-02
A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand
Peplin
Phase 2 Completed
NCT00916006 2015-04-02
A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
Peplin
Phase 3 Completed
NCT00107965 2015-03-25
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses
Peplin
Phase 2 Completed
NCT00239135 2015-03-25
Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
Peplin
Phase 2 Completed
NCT00742391 2015-03-06
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Peplin
Phase 3 Completed
NCT00852137 2015-03-06
A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
Peplin
Phase 2 Completed
NCT00915551 2015-03-06
A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
Peplin
Phase 3 Completed
NCT00942604 2015-03-06
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Peplin
Phase 3 Completed
NCT00544258 2015-02-12
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005
Peplin
Phase 1 Completed
NCT00108121 2015-01-19
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
Peplin
Phase 2 Completed
NCT00329121 2015-01-19
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ
Peplin
Phase 2 Completed
NCT02242747 2014-09-17
Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis
University of Sao Paulo
Phase NA Completed
NCT01836367 2013-12-31
Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT01214564 2011-01-25
Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis
Peplin
Phase 2 Completed
NCT00108134 2008-12-24
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma
Peplin
Phase 2 Completed